Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...
Medicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression aft ...
Future Market Insights21m
United States Countertop Industry Set for Robust Growth, Projected to Expand at 6.1% CAGR Through 2033
The United States countertop industry revenue is projected to total USD 76,783.0 million in 2023 and USD 138,218.8 million by ...